Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of CPT + thalidomide + dexamethasone versus placebo + thalidomide + dexamethasone in relapsed or refractory multiple myeloma
ChiCTR-IPR-15006024Phase 3Recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Dec 2014
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aponermin in multiple myeloma (MM) (2 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoint: Progression-free survival. Started Dec 2014; status: recruiting.
02
Drugs
aponermin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR-IPR-15006024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006024.